Realist has demonstrated that γδ T cells can be activated to target a series of well-known glycolipid tumor markers or TMGs, which is a new discovery about how γδ T cells work. TMGs are highly overexpressed in a wide variety of cancers, including: melanoma, leukemia, lymphoma, neuroblastoma, soft tissue sarcoma, osteosarcoma, lung cancer and many more.
Realist’s lead products target GD2 and GD3, which are clinically validated TMG targets. Our products have demonstrated high efficacy (without safety and toxicity issues) against both metastases and primary tumors in four aggressive preclinical tumor models (i.e. lymphoma, melanoma and small cell lung cancer).